Erratum: miR-153 Supports Colorectal Cancer Progression via Pleiotropic Effects That Enhance Invasion and Chemotherapeutic Resistance (Cancer Res (2013) 73 (6435–6447) DOI: 10.1158/0008-5472.CAN-12-3308);MiR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance

Cancer Research

Volumn 73, Issue 21, 2013, Pages 6435-6447

  Zhang, Lei ^a   Pickard, Karen ^a   Jenei, Veronika ^a   Bullock, Marc D ^a   Bruce, Amanda ^a   Mitter, Richard ^c   Kelly, Gavin ^c   Paraskeva, Christos ^d   Strefford, John ^a   Primrose, John ^a   Thomas, Gareth J ^a   Packham, Graham ^a   Mirnezami, Alex H ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GELATINASE B; MICRORNA; MICRORNA 153; OXALIPLATIN; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DRUG TARGETING; ENZYME INDUCTION; ENZYME SYNTHESIS; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; TUMOR INVASION; TUMOR XENOGRAFT; UPREGULATION;

EID: 84887196682     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-22-0501     Document Type: Erratum

References (51)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe. Ann Oncol 2005;16: 481-8.
2. Andre N, Schmiegel W. Chemoradiotherapy for colorectal cancer. Gut 2005;54: 1194-202.
3. Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006;93: 1115-22.
4. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009;27: 5848-56.
5. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al.Human microRNAgenes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101: 2999-004.
6. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136: 215-33.
7. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008;27: 2128-36.
8. Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F, et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A 2010;107: 6982-87.
9. Lanza G, Ferracin M, Gafa R, Veronese A, Spizzo R, Pichiorri F, et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer 2007;6: 54.
10. Rossi S, Di Narzo AF, Mestdagh P, Jacobs B, Bosman FT, Gustavsson B, et al. MicroRNAs in colon cancer: a roadmap for discovery. FEBS Lett 2012;586: 3000-07.
11. Schetter AJ, LeungSY, Sohn JJ, Zanetti KA,BowmanED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299: 425-36.
12. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007;449: 682-88.
13. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM,WangZC, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009;137: 1032-46.
14. Bergmann-Leitner ES, Abrams SI. Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL. J Immunol 2000;164: 4941-54.
15. Hewitt RE, McMarlin A, Kleiner D, Wersto R, Martin P, Tsokos M, et al. Validation of a model of colon cancer progression. J Pathol 2000;192: 446-54.
16. Huerta S, Baay-Guzman G, Gonzalez-Bonilla CR, Livingston EH, Huerta-Yepez S, Bonavida B. In vitro and in vivo sensitization ofSW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: involvement of AIF. Nitric Oxide 2009;20: 182-94.
17. Nyström ML, Thomas GJ, Stone M, Mackenzie IC, Hart IR, Marshall JF. Development of a quantitative method to analyse tumour cell invasion in organotypic culture. J Pathol 2005;205: 468-75.
18. Association of Coloproctology of Great Britain and Ireland. Guidelines for the management of colorectal cancer. 3rd ed. London: Association of Coloproctology of Great Britain and Ireland, 2007.
19. Parker H, Rose-Zerilli MJ, Parker A, Chaplin T, Wade R, Gardiner A, et al. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia 2011;25: 489-97.
20. Lamy P, Andersen CL, Dyrskjøt L, Tørring N, Rntoft T, Wiuf C. Are microRNAs located in genomic regions associated with cancer? Br J Cancer 2006;95: 1415-18.
21. Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations and gene fusions in cancer. Available from: http://cgap.nci.nih.gov/ Chromosomes/Mitelman. Access Feb 13, 2012.
22. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141: 52-67.
23. Zeng ZS, Huang Y, Cohen AM, Guillen JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996;14: 3133-40.
24. Benton G, Kleinman HK, George J, Arnaoutova I. Multiple uses of basement membrane-like matrix (BME/Matrigel) in vitro and in vivo with cancer cells. Int J Cancer 2011;128: 1751-57.
25. Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther 2010;17: 523-31.
26. Ory B, Ramsey MR, Wilson C, Vadysirisack DD, Forster N, Rocco JW, et al. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest 2011;121: 809-20.
27. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362: 1273-81.
28. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7: 573-84.
29. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007;128: 309-23.
30. Fernandez de Mattos S, Villalonga P, Clardy J, Lam EW. FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Mol Cancer Ther 2008;7: 3237-46.
31. Arimoto-Ishida E, Ohmichi M, Mabuchi S, Takahashi T, Ohshima C, Hayakawa J, et al. Inhibition of phosphorylation of a forkhead transcription factor sensitizes human ovarian cancer cells to cisplatin. Endocrinology 2004;145: 2014-22.
32. Shiota M, Yokomizo A, Kashiwagi E, Tada Y, Inokuchi J, Tatsugami K, et al. Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin. Cancer Sci 2010;101: 1177-85.
33. Chock KL, Allison JM, Shimizu Y, El Shamy WM. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells. Cancer Res 2010;70: 8782-91.
34. Fang L, Wang H, Zhou L, Yu D. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells. Toxicol Appl Pharmacol 2011;251: 8-15.
35. Gao J, Yang X, Yin P, Hu W, Liao H, Miao Z, et al. The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer. Int J Oncol 2012;40: 1203-9.
36. Yuan Z, Wang F, Zhao Z, Zhao X, Qiu J, Nie C, et al. BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells. PLoS One 2011;6:e20586.
37. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, et al. Mammalian SIRT1 represses Forkhead transcription factors. Cell 2004;116: 551-63.
38. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19: 92-105.
39. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol 2004;5:R13.
40. Doxakis E. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J Biol Chem 2010;285: 12726-34.
41. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008;6: 14.
42. Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L, et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 2010;70: 367-77.
43. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 2012;72: 3499-511.
44. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology 2010;138: 2059-72.
45. Yamagata S, Ito Y, Tanaka R, Shimizu S. Gelatinases of metastatic cell lines of murine colonic carcinoma as detected by substrate-gel electrophoresis. Biochem Biophys Res Commun 1988;151: 158-62.
46. Bauerschlag DO, Ammerpohl O, Bräutigam K, Schem C, Lin Q, Weigel MT, et al. Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles. Oncology 2011;80: 12-20.
47. Kim HR, Wheeler MA, Wilson CM, Iida J, Eng D, Simpson MA, et al. Hyaluronan facilitates invasion of colon carcinoma cells in vitro via interaction with CD44. Cancer Res 2004;64: 4569-76.
48. Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S, Syrjänen K, et al. MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer Invest 2010;28: 38-43.
49. Waas ET, Wobbes T, Lomme RM, DeGroot J, Ruers T, Hendriks T. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg 2003;90: 1556-64.
50. You H, Mak TW. Crosstalk between p53 and FOXO transcription factors. Cell Cycle 2005;4: 37-38.
51. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009;69: 1279-83.